Dec 4 (Reuters) - INNATE PHARMA ::ANNOUNCED ON MONDAY UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME.DIFFERENTIATING PROFILE OF IPH4102 CONFIRMED: HIGH AND DURABLE RESPONSE, FAVORABLE SAFETY PROFILE WITH LONG-TERM FOLLOW-UP AND SUBSTANTIAL IMPROVEMENT IN QUALITY OF LIFE.EXPECTS TO INITIATE A GLOBAL PHASE II STUDY ("TELLOMAK") IN DIFFERENT SUBTYPES OF T-CELL LYMPHOMAS IN THE FIRST HALF OF 2019.
Full Article
Sept 14 (Reuters) - Innate Pharma SA ::INNATE PHARMA REPORTS FIRST HALF 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.
Full Article
Sept 14 (Reuters) - INNATE PHARMA SA ::H1 REVENUE EUR 23.7 MILLION VERSUS EUR 21.3 MILLION YEAR AGO.H1 OPERATING LOSS EUR 15.7 MILLION V LOSS OF EUR 18.2 MILLION YEAR AGO.H1 NET LOSS EUR 16.1 MILLION VERSUS LOSS OF EUR 23.4 MILLION YEAR AGO.
Full Article
Sept 14 (Reuters) - Innate Pharma SA ::REG-INNATE PHARMA REPORTS FIRST HALF 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.CASH POSITION EUR 141.6M (MILLION EUROS) AS OF JUNE 30, 2018.NEW CLINICAL AND TRANSLATIONAL DATA FOR MONALIZUMAB AND IPH4102 TO BE PRESENTED AT UPCOMING MEDICAL CONFERENCES.H1 REVENUE AND OTHER INCOME AMOUNTING TO EUR 23.7M (EUR 21.2M FOR FIRST HALF OF 2017).A NET LOSS FOR FIRST HALF OF 2018 AMOUNTING TO EUR 16.2M (EUR 16.6M FOR FIRST HALF OF 2017)..
Full Article
May 17 (Reuters) - INNATE PHARMA SA ::PRELIMINARY ACTIVITY OBSERVED OF THE COMBINATION OF MONALIZUMAB AND DURVALUMAB IN PATIENTS WITH COLORECTAL CANCER.3 PARTIAL RESPONSES (PR) AND 11 STABLE DISEASE (SD) RESPONSE AMONG 37 PATIENTS EVALUABLE FOR EFFICACY.DISEASE CONTROL RATE (DCR) AT 16 WEEKS WAS 24%.MANAGEABLE TOXICITY PROFILE DEMONSTRATED.
Full Article
May 16 (Reuters) - Innate Pharma SA ::REG-INNATE PHARMA : FIRST QUARTER 2018 REPORT.END Q1 CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF COMPANY AMOUNTED TO EUR 153.8 MILLION.SIGNIFICANT MOMENTUM ACROSS PORTFOLIO.Q1 CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF COMPANY AMOUNTED TO EUR 153.8 MILLION.REVENUES FOR Q1 OF 2018 AMOUNTED TO EUR 8.7 MILLION (EUR 7.8 MILLION FOR SAME PERIOD IN 2017).
Full Article
March 8 (Reuters) - INNATE PHARMA SA ::FY REVENUE AND OTHER INCOME EUR 44.0 MILLION VERSUS EUR 65.7 MILLION YEAR AGO.FY OPERATING LOSS EUR 40.0 MILLION VERSUS INCOME EUR 7.6 MILLION YEAR AGO.FY NET LOSS EUR 48.4 MILLION VERSUS INCOME EUR 12.6 MILLION YEAR AGO.CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS AMOUNTED TO EUR 176.6 MILLION AS OF DEC. 31.IPH5401 WILL ENTER FIRST CLINICAL STUDIES IN ONCOLOGY IN 2018.EXPECTS CLINICAL READ-OUTS FOR BOTH MONALIZUMAB AND IPH4102 PROGRAM IN 2018.
Full Article
Jan 8 (Reuters) - Innate Pharma Sa ::REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER.
Full Article
Nov 22 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA PROVIDES AN UPDATE ON LIRILUMAB.LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS.COMBINATION OF NIVOLUMAB PLUS LIRILUMAB IN EXTENDED POPULATION OF PATIENTS WITH SCCHN DID NOT PROVIDE CLEAR EVIDENCE OF BENEFIT TO PATIENTS OR OBVIOUS DEVELOPMENT PATH.ON COMBINATION OF NIVOLUMAB PLUS LIRILUMAB: DISCUSSIONS ARE ONGOING REGARDING NEXT STEPS.AN UPDATE IS PLANNED FOR EARLY 2018.
Full Article
Nov 15 (Reuters) - INNATE PHARMA SA ::Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO.9 MONTH REVENUE EUR 27.9 MILLION VERSUS EUR 27.9 MILLION YEAR AGO.CASH POSITION AT SEPT 30 EUR 195.7 MILLION VERSUS EUR 239.6 MILLION YEAR AGO.
Full Article
Earnings vs. 
Estimates